PARP inhibitors increase the resistance of tumor cells to T cell-mediated cell death by upregulating PD-L1, whereas blocking PD-L1 can make cancer cells that have been treated with PARP inhibitors more susceptible to T cell killing. This evidence concerns the gene PARP1 and neoplasm.